Immunotherapy in Upper GI Cancers: A Multidisciplinary Discussion of the Data and Real-World Barriers Faced in Practice

1. Evaluate current guideline-recommended immunotherapy regimens based on the most up-to-date clinical trial data in gastric, GEJ, and EAC cancers.

2. Utilize appropriate testing strategies for PD-L1 expression as part of selection and sequencing of currently available therapies for gastric, GEJ, and EAC cancer.

3. Integrate an interprofessional approach to supportive care that addresses real-world barriers and AEs for patients with gastric, GEJ, and EAC cancers.

Supported through an independent educational grant from Bristol Myers Squibb.

Physicians, pharmacists, nurses, nurse practitioners (NPs), physician associates (PAs) and other allied health care professionals specializing in medical or surgical oncology, gastroenterology, or pathology.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty:

Yelena Y. Janjigian, MD—reports the following financial relationships:
Consultant—AbbVie Inc., AmerisourceBergen Corporation, Arcus Biosciences Inc., AskGene Pharma Inc., AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb Company, Daiichi Sankyo Inc., Gaurdant Health, Geneos Therapeutics, GSK, Imedex, Imugene, Lilly, Lynx Health, Merck & Co. Inc., Merck Serono, Mersana Therapeutics, Michael J. Hennessy Associates, Paradigm Medical Communications, PeerView, Pfizer Inc., Research To Practice, RGENIX, Seagen Inc., Silverback Therapeutics, and Zymeworks Inc.
Research support—Bayer, Bristol Myers Squibb Company, Cycle for Survival, Fred’s Team, Genentech Inc./Roche, Lilly, Merck & Co. Inc., National Cancer Institute (NCI), RGENIX, and the U.S. Department of Defense
Stock shareholder (direct purchase)—RGENIX

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO—reports the following financial relationships:
Consultant—Amgen Inc., Erasca, and Janssen Pharmaceuticals Inc.
Research support/funding to his institution—Abbisko Therapeutics, AbbVie Inc., ADC Therapeutics, Amgen Inc., Bayer, Bristol Myers Squibb Company, GSK, Incyte, Inhibrx Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Meryx, MorphoSys, Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi, Takeda Pharmaceuticals USA Inc., Turning Point Therapeutics Inc., and Xenco

Kelley A. Rone, DNP, RN, AGNP-c—has no relevant financial relationships to disclose in relation to the content of this activity.

Kurt A. Schalper, MD, PhD—reports the following financial relationships:
Advisory board—AstraZeneca, Bristol Myers Squibb Company, EMD Serono, Genmab, Merck & Co. Inc., Molecular Templates Inc., OnCusp, Parthenon Therapeutics Inc., Shattuck Labs Inc., Takeda Pharmaceuticals USA Inc., and Torque Therapeutics/Repertoire Immune Medicines
Consultant—Agenus Inc., Clinica Alemana Santiago, Roche, and Takeda Pharmaceuticals USA Inc.
Research support—Akoya Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co. Inc., Moderna Inc., Navigate BioPharma Services Inc., Pierre Fabre, Ribon Therapeutics, Roche, Surface Oncology, Takeda Pharmaceuticals USA Inc., and Tesaro/GSK
Speakers bureau—Forefront Collaborative and PeerView

The following individuals have no financial relationships to disclose:

• Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
• Nichole Lainhart (Planning Committee/ME)
• David Modrak, PhD (Planning Committee/MRG)
• Katherine Lee, PharmD (Planning Committee/MRG)
• Susan H. Yarbrough, CHCP (Planning Committee)
• Sandra Caballero, PharmD (Planning Committee)
• Sharon Tordoff (Planning Committee)

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA)  of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.